ArticleMammalian genome : official journal of the International Mammalian Genome Society2025
Multi-omics dissection of RAD21-PON1 axis reveals metabolic-immune crosstalk and prognostic significance in hepatocellular carcinoma.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrative analysis and experiment validation of SLC12A8 as a biomarker for the malignant transition from endometriosis to endometriosis associated ovarian cancer.Functional & integrative genomics · 2026Article
- Graph informed biomarker discovery framework using transcriptomic machine learning for glioblastoma prognosis.Scientific reports · 2026Article
- Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
RAD21, a key cohesin subunit, participates in chromatin regulation and may influence tumor metabolism and immunity. Its role in liver HCC remains unclear. We investigated whether RAD21 regulates PON1 and how this axis integrates metabolic and immune signals in HCC. Multi-omics integration (transcriptomic, ChIP-seq, and scRNA-seq) datasets to identify the RAD21-PON1 regulatory axis, with immune infiltration, metabolic remodeling, and prognostic impact assessed via GSVA, TIDE, and LASSO modeling. RAD21 upregulation inversely correlated with PON1 expression. RAD21 binds the promoter of PON1, impacting metabolic pathway activity and shaping the immune microenvironment. Low PON1 expression was linked to immunosuppressive patterns and poor prognosis. A RAD21-PON1 risk signature robustly stratified survival. Our findings highlight the RAD21-PON1 axis as a central regulator connecting metabolism and immunity in HCC, providing prognostic and therapeutic insights.
Indexed as
Identifiers
41143965What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.